PDF(1544 KB)
Advances in clinical research on C1q nephropathy
YANG Juan, ZHANG Bi-Li
Chinese Journal of Contemporary Pediatrics ›› 2016, Vol. 18 ›› Issue (11) : 1194-1198.
PDF(1544 KB)
PDF(1544 KB)
Advances in clinical research on C1q nephropathy
C1q nephropathy is a rare type of glomerulonephritis manifested as the deposition of C1q in the glomerular mesangium during immunofluorescent staining. Systemic lupus erythematosus and type I membranoproliferative glomerulonephropathy need to be excluded in the diagnosis of C1q nephropathy. C1q nephropathy has various manifestations under a light microscope, mainly including minimal change disease, focal segmental glomerulosclerosis, and proliferative glomerulonephritis. This disease is mainly manifested as persistent proteinuria or nephrotic syndrome and occurs more frequently in boys. Currently, glucocorticoids are mainly used for the treatment of this disease. Patients with C1q nephropathy show a good response to immunosuppressant treatment, but have a high rate of glucocorticoid resistance. Therefore, in this case, methylprednisolone pulse therapy or a combination with immunosuppressant treatment helps to achieve a good prognosis.
C1q nephropathy / Histological feature / Treatment / Prognosis / Child
[1] Jennette JC,Hipp CG.Clq nephropathy:A distinct pathologic entity usually causing nephrotic syndrome[J].Am J Kidney Dis,1985,6(2):103-110.
[2] Malleshappa P,Vankalakunti M.Diverse clinical and histology presentation in C1q nephropathy[J].Nephrourol Mon,2013,5(3):787-791.
[3] Devasahayam J,Erode-Singaravelu G,Bhat Z,et al.C1q Nephropathy:The unique underrecognized pathological entity[J].Anal Cell Pathol (Amst),2015,2015:490413.
[4] Gunasekara VN,Sebire NJ,Tullus K.C1q nephropathy in children:clinical characteristics and outcome[J].Pediatr Nephrol,2014,29(3):407-413.
[5] Wenderfer SE,Swinford RD,Braun MC.C1q nephropathy in the pediatric population:pathology and pathogenesis[J].Pediatr Nephrol,2010,25(8):1385-1396.
[6] van den Dobbelsteen ME,van der Woude FJ,Schroeijers WE,et al.Both IgG-and C1q-receptors play a role in the enhanced binding of IgG complexes to human mesangial cells[J].J Am Soc Nephrol,1996,7(4):573-581.
[7] Malleshappa P.C1q nephropathy-unity in diversity[J].J Renal Inj Prev,2013,2(4):117-118.
[8] Chaves J,Beirão I,Balreira A,et al.Progressive myoclonus epilepsy with nephropathy C1q due to SCARB2/LIMP-2 deficiency:clinical report of two siblings[J].Seizure,2011,20(9):738-740.
[9] Ma R,Cui Z,Hu SY,et al.The alternative pathway of complement activationmay be involved in the renal damage of human anti-glomerular basement membrane disease[J].PLoS One,2014,9(3):e91250
[10] Boqari DT,Al Faraj S,Arafah M,et al.Herb-induced acute bone marrow intoxication and interstitial nephritis superimposing glomerular C1q deposition in a patient with paroxysmal nocturnal hemoglobinuria[J].Saudi J Kidney Dis Transpl,2015,26(3):572-579.
[11] Tibor Fülöp T,CsongrádiÉ,Lerant AA,et al.Resolution of C1q deposition but not of the clinical nephrotic syndrome after immunomodulating therapy in focal sclerosis[J].J Nephropathol,2015,4(2):54-58.
[12] Takano T,Elimam H,Cybulsky AV.Complement-mediated cellular injury[J].Semin Nephrol,2013,33(6):586-601.
[13] Lee HJ,Choi SY,Jeong KH,et al.Association of C1q deposition with renal outcomes in IgA nephropathy[J].Clin Nephrol,2013,80(2):98-104.
[14] Vizjak A,Ferluga D,Rozic M,et al.Pathology,clinical presentations,and outcomes of C1q nephropathy[J].J Am Soc Nephrol,2008,19(11):2237-2244.
[15] Mandal SN,Jha R,Fatima R,et al.Non-nephronal hematuria misdiagnosed as C1q nephropathy:Look before you leap[J].Indian J Nephrol,2012,22(3):206-209.
[16] Said SM,Cornell LD,Valeri AM,et al.C1q deposition in the renal allograft:a report of 24 cases[J].Mod Pathol,2010,23(8):1080-1088.
[17] Lau KK,Gaber LW,Delos Santos NM,et al.C1q nephropathy:features at presentation and outcome[J].Pediatr Nephrol,2005,20(6):744-749.
[18] Malleshappa P,Ranganath R,Chaudhari AP,et al.C1q nephropathy presenting as acute renal failure[J].Saudi J Kidney Dis Transpl,2011,22(2):324-326.
[19] Galeši?K,Horvati?I,Batini?D,et al.C1Q Nephropathy:case reports and literature review[J].Lijec Vjesn,2015,137(9-10):283-287.
[20] Reeves-Daniel AM,Iskandar SS,Bowden DW,et al.Is collapsing C1q nephropathy another MYH9-associated kidney disease? A case report[J].Am J Kidney Dis,2010,55(5):e21-24.
[21] Zhao Y,Fan H,Bao BY,et al.C1q nephropathy in an old woman with acute renal failure:a case report and literature review[J].Ren Fail,2014,36(7):1136-1138.
[22] Mokhtar GA,Jalalah SM.A Clinicopathological study of C1q nephropathy at King Abdulaziz University[J].Iran J Kidney Dis,2015,9(4):279-285.
[23] Kanodia KV,Vanikar AV,Patel RD,et al.C1q nephropathy in India:A single-center study[J].Saudi J Kidney Dis Transpl,2015,26(2):398-403.
[24] Bhowmik DM,Jain S,Dinda AK,et al.C1q nephropathy presenting as nephritic-nephrotic syndrome[J].Saudi J Kidney Dis Transpl,2011,22(3):561-563.
[25] Taggart L,Harris A,El-Dahr S,et al.C1q nephropathy in a child presenting with recurrent gross hematuria[J].Pediatr Nephrol,2010,25(1):165-168.
[26] Fukuma Y,Hisano S,Segawa Y,et al.Clinicopathologic correlation of C1q nephropathy in children[J].Am J Kidney Dis,2006,47(3):412-418.
[27] 赵三龙,黄松明,张维真,等.儿童C1q肾病4例报告[J].临床儿科杂志,2010,28(4):337-340.
[28] Wenderfer SE,Swinford RD,Braun MC.C1q nephropathy in the pediatric population:pathology and pathogenesis[J].Pediatr Nephrol,2010,25(8):1385-1396.
[29] Gunasekara VN,Sebire NJ,Tullus K.C1q nephropathy in children:clinical characteristics and outcome[J].Pediatr Nephrol,2014,29(3):407-413.
[30] Deurwaarder ES,Steenbergen EJ,Hoogeveen EK.et al.Membranous nephropathy with predominance of C1q:another variant of C1q nephropathy[J].Clin Nephrol,2012,77(6):501-504.
[31] O'Flynn J,Flierman R,van der Pol P,et al.Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation[J].Mol Immunol,2011,49(1-2):75-83.
[32] Maliakkal JG,Liapis H,White AJ,et al.C1q nephropathy in the setting of granulomatosis with polyangiitis treated with tacrolimus[J].Clin Kidney J,2014,7(5):499-500.
[33] Kim J,Patnaik N,Chorny N,et al.Second-line immunosuppressive treatment of childhood nephrotic syndrome:a single-center experience[J].Nephron Extra,2014,4(1):8-17.
[34] Fogo AB,Lusco MA,Najafian B,et al.AJKD atlas of renal pathology:C1q Nephropathy[J].Am J Kidney Dis,2015,66(3):13-14.
[35] Rocha S,Carvalho MJ,Lobato L,et al.C1q nephropathy and malignancy[J].Nefrologia,2012,32(2):270-272.
[36] Sinha A,Nast CC,Hristea I,et al.Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy[J].Clin Exp Nephrol,2011,15(1):164-170.
[37] 倪兆慧,金海姣,徐维佳.C1q肾病的诊断及治疗[J].中华肾病研究电子杂志,2015,4(5),232-235.
[38] 刘喆,张碧丽.儿童C1q肾病二例[J].天津医药,2014,42(10):1054-1055.
[39] 赵三龙,黄松明,朱春华,等.儿童Clq肾病的临床病理特点及治疗[J].中华肾脏病杂志,2011,27(12):877-883.
[40] Spreitzer MV,Vizjak A,Ferluga D,et al.Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome[J].Pediatric Nephrol,2014,29(1):67-74.
[41] Kersnik Levart T,Kenda RB,Avgustin Cavi?M,et al.C1Q nephropathy in children[J].Pediatr Nephrol,2005,20(12):1756-1761.
